clinical trial · NCT05406622
MOTIV BTK Randomized Controlled Trial
REVA Medical, Inc.·N/A·active not recruiting·n = 292
Critical Limb IschemiaMOTIV Sirolimus-Eluting Bioresorbable ScaffoldPercutaneous Transluminal Angioplasty (PTA) Device
brief summary
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
started
Jun 10, 2022
primary completion
Apr 30, 2026
completion
Mar 31, 2030
last updated
Jun 15, 2026
official title
A Prospective, Multicenter, Single Blind, Randomized Controlled Trial Evaluating the Safety and Effectiveness of the MOTIV Sirolimus-Eluting Bioresorbable Vascular Scaffold Compared With Plain Balloon Angioplasty for the Treatment of Infrapopliteal Lesions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol